European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Empowered Patient Podcast: Treating Atopic Dermatitis with Neal Koller, CEO, Alphyn Biologics

Empowered Patient Podcast: Treating Atopic Dermatitis Using Therapeutic Drug Containing Multiple Bioactive Compounds with Neal Koller Alphyn Biologics NEWS PROVIDED BY Alphyn Biologics Feb 27, 2023 Neal Koller, CEO of Alphyn Biologics, discusses their first topical drug which treats both atopic dermatitis and atopic dermatitis with secondary infection.   Listen to the podcast here. CONTACTS…